pDNAVACC-Ultra™ family of vectors

NTC PRODUCTS AND SERVICES


VECTORS
X
Mammalian Vectors
XAntibiotic-Free Vecotrs
XRig-I Activating Vectors
XpDNAVACCUltra Vector
XLinear Vectors
XRecombineering Vectors
XAutolytic E. coli Cell Lines
XGene Sllencing (transient)
XGene Sllencing (retroviral, stable)
XAnti-Silencing Elements

CELL LINES
XAutolytic E. coli Cell Lines

DNA VACCINES
XXX
DNA Vaccine References
XXX
Pricing
XXXX
PRECISION CLONING
XX
Services and Pricing

RECOMBINANT PROTEINS
X
pVEX™
X
Fluorescent Proteins

PLASMIDS
XSmall Scale Plasmid DNA
XSmall Scale C of A
XLarge Scale Plasmid DNA
XLarge Scale C of A
XPlasmid DNA Order Form
XE. coli Cell paste
XPlasmid Detox Service, NEW!
X
DNA FERMENTATION PROCESS
X
HyperGRO™ Process
X
HyperGRO™ Licensing
X
HyperGRO™ Pricing

PROCESS DEVELOPMENT
X
Process Development Basics
X
Process Licensing

HYPERTAQ™ DNA POLYMERASE


NTC Contacts:

Email: support@natx.com
Phone: (402) 472-6530
Fax: (402) 472-6532

site map | home | contact us


XXVersions


pDNAVACCultra3

XXDescription

pDNAVACC-Ultra™ family of vectors, is a rapidly deployable set of DNA vaccination tools that can be readily adapted to any antigens in a one to two-week antigen turnaround service.

NTC’s pDNAVACCUltra™ vectors represent a targeted approach to expression, immunogenicity, trafficking (secreted, endosomal, membrane-anchored, proteasomal, native), and regulatory compliance.  These vectors have proven effective at providing high-level protection (70-100%) in animals, against a variety of microbial antigens: plague, anthrax, influenza, rabies, and other virus. They can be used alone, or in combination with other forms of antigen for prime-boost regimens. The high levels of expression attained from the Ultra-CMV promoter and transcriptional modifications regularly beat the expression and immunogenicity of previous generation ‘Gold Standard’ vectors.

XXFeatures of NTC's vectors featured in the Vector Selection Flowchart:


• Enhanced antigen expression in mammalian cells
• Compliance with FDA guidance
• Improved antibody response
• Improved antibody avidity
• Kanamycin or RNA-OUT (antibiotic free) selectable markers
• Improved DNA backbone for maximum plasmid production (>2.6g/L)
• Optimized, chimeric promoter-intron (SV40-CMV-HTLV-1 R-U5-synthetic intron) for max expression/immunogenicity
• Superior E. coli plasmid production yields  from improved origin of replication (>2.6g/L)
• Destination targeting – secreted, endosomal, membrane anchored, proteasomal, native – for directed, or mixed presentation
• Compliance with regulatory guidance for DNA vaccine vectors – all non-essential sequences removed, backbone optimized for non-homology to human genome
•  Seamless cloning of antigens, and antigen cloning services available (RapidVACC)
• Optional antibiotic-free backbones and Type 1 interferon activating RNA elements (RNAe).

X Vector Specifications:


pDNAVACCultra3

DNA Vaccine Vector, pDNAVACCultra3


Vector Features: pDNAVACCUltra3, a typical DNA vaccine plasmid backbone: trpA prokaryotic terminator: 3308-16; pUC replication origin: 23-1037; Kanamycin resistance marker: 1045-1965; Fd gene VIII prokaryotic terminator:1972-2015; tonB bidirectional terminator: 2023-2060; CMV enhancer: 2078-2635; CMV promoter: 2636-2755; Untranslated leader (exon 1): 2756-2807; Intron: 2808-2933; Kozak sequence (exon 2):2934-2942; TPA N-terminal targeting tag: 2943-3011; SapI cloning cassette: 3012-3048; GPI C-terminal targeting tag: 3049-3147; Eukaryotic terminator: 3158-3297.

Contact NTC, Toll free: 1-(888) WIZ-BANG

Plasmids, Recombinant Proteins, DNA Vaccines, Viral Vectors, Therapeutic Genes, Fermentation Technology for Gene Therapy and Biotechnology
NTC's free resource "Site" for the biotechnology industry,
including Databases and Sequences Analysis Tool
s



WWW http://www.natx.com